Method of producing nucleic acid library and composition and kit for practicing the same
Patent Information
- Application Number
- JP2024125563
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-06
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024161413000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application No. 62 / 681,524, filed June 6, 2018. No. 60 / 339,933, filed on Oct. 23, 2007, which claims the benefit of US Provisional Patent Application No. 60 / 339,933, filed on Oct. 23, 2007, the disclosure of which is incorporated herein by reference in its entirety. [Background technology]
[0002] Nucleic acid sequencing has become an increasingly important branch of genetic research due to its use in diagnostics and other applications. In general, nucleic acid sequencing involves the determination of the length of a nucleic acid, such as a fragment of RNA or DNA. The study involves determining the sequence of a nucleic acid fragment that is amplified by a nucleic acid sequence analysis. Relatively short sequences are typically analyzed and The sequence information provided reliably determines the sequence of the much larger length of genetic material from which the fragments were derived. To determine the sequence of interest, the fragments are aligned against a reference sequence or the fragments are logically matched together. The characteristic fragments can be used in various bioinformatics methods to Automated computer-based tests have been developed to map genomes and characterize genetic variation between individuals. It has been used more recently for analysis, identification of genes and their functions, etc.
[0003] Some methods used in high-throughput DNA sequencing include universal amplification reactions. It relies on a method whereby a DNA sample is randomly fragmented and then the different fragments are separated. The ends are engineered to all contain the same DNA sequence. Can be amplified in a single reaction with a single amplification primer pair. Addition of universal priming sequences to the ends of targets to be sequenced can be accomplished in a variety of ways. For example, a nucleic acid sequence having a universal sequence at its 5' end and a degenerate sequence at its 3' end can be used. Use universal primers to target complex sequences or complex mixtures of target sequences. The 3' degenerate portion of the primer can amplify random fragments from the DNA. It anneals at random positions, is extended, and has a universal sequence at its 5' end. It can create copies of the target.
[0004] Alternatively, adaptors containing universal priming sequences can be ligated to the ends of the target sequences. One or more adaptors can undergo ligation reactions with the target sequence. Ligation of one or more adapter sequences for universal amplification Disadvantages associated with current methods for preparing nucleic acid sequencing libraries via extraction include: The time and expense involved in such a process. Summary of the Invention
[0005] A method for generating a nucleic acid library is provided. The method comprises binding to a single-stranded nucleic acid binding protein. The combined single-stranded nucleic acid (SSB-linked ssNA), adapter oligonucleotide, and splice Combine the splint oligonucleotides to form the SSB-linked ssNA ends. A splint oligonucleotide hybridized to the end region and an adaptor oligonucleotide The method further comprises forming a complex containing a first adaptor oligonucleotide. The end is the first terminal region of the SSB-bound ssNA. n) adjacent to an end of the Compositions and kits are also provided that find use, for example, in practicing the methods of the disclosure. . [Brief description of the drawings]
[0006] [Figure 1] Schematic diagram of a method for generating a nucleic acid library according to one embodiment of the present disclosure. [Diagram 2] Comparison of an exemplary method of the present disclosure with other methods on degraded DNA (top panel) and modern DNA (bottom panel). [Diagram 3] Hair DNA length distribution. The left panel shows the observed lengths of template molecules generated by the Santa Cruz method (SRL3) from modern hair DNA. As expected for DNA in the hair shaft, the lengths of the intact molecules are generally short. A similar length distribution is shown in the right panel (SRL4). [Figure 4] Estimated library complexity (number of unique molecules) in SRL3 and SRL4. [Diagram 5] Library complexity comparison. Sequencing libraries were generated using the exemplary methods of this disclosure, SS2.0, BEST, and forked adaptor ligation. Library complexity (number of unique molecules in the library) was estimated from millions of reads using Preseq (left) or via qPCR (right) in triplicate experiments. The exemplary method of this disclosure converts 2-3x more extracted DNA into sequencing libraries than the next best protocol, SS2.0. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] A method for generating a nucleic acid library is provided. The method comprises binding to a single-stranded nucleic acid binding protein. The combined single-stranded nucleic acid (SSB-linked ssNA), adapter oligonucleotide, and splice The lint oligonucleotides were combined to bind the terminal region of the SSB-bound ssNA and the adapter A complex comprising a splint oligonucleotide hybridized to the oligonucleotide The end of the first adaptor oligonucleotide is an SSB-linked s and the method further comprises covalently linking the adjacent ends to a first terminal region of the sNA. Compositions and methods that find use, for example, in practicing the methods of the present disclosure. Kits are also provided.
[0008] Before describing the methods, compositions, and kits of the present disclosure in more detail, The kits are not limited to the specific embodiments described, which may, of course, vary. It should be understood that the scope of the methods, compositions, and kits is set forth in the accompanying claims. The terms used herein refer to specific embodiments only as defined by the claims. It is also understood that this is for illustrative purposes only and is not intended to be limiting. I want to be.
[0009] Where a range of values is given, there shall be no clear indication in the context between the upper and lower limits of the range. Each intervening value, and any other stated value, to the tenth of the unit unless the lower limit is exceeded or any intervening value within the stated range is encompassed in the methods, compositions, and kits. It should be understood that the upper and lower limits of these smaller ranges may independently exceed the smaller ranges. and, except for any specifically excluded limits within the ranges described, they also include the method, Compositions, compositions, and kits. In the case of a method, composition, or method according to the present invention, a range excluding one or both of those inclusive limits is also included. , and included in the kit.
[0010] Certain ranges are presented herein with numerical values preceded by the term "about." The term "about" as used herein refers to the exact number which it precedes, as well as to the extent that the term precedes it. Provide textual support for numbers that are close to or approximately equal to the number you want to In determining whether a number is near or approximately equal to a specified number, Any numbers that are not specified but are suggested are specifically stated in the context in which they are presented. The number may be substantially equivalent to the number.
[0011] Unless otherwise defined, all technical and scientific terms used herein are defined by the The methods, compositions, and kits are generally understood by those of ordinary skill in the art to which they pertain. Any methods, compositions similar or equivalent to those described herein. The methods, compositions, and kits can also be used to practice or test the methods, compositions, and kits. Although various methods, compositions, and kits can be used, representative illustrative methods, compositions, and kits are described herein.
[0012] All publications and patents cited herein are hereby incorporated by reference in their entirety. are incorporated by reference as if each such claim were specifically and individually indicated to be incorporated by reference. Related methods and / or materials incorporated herein and whose publications are cited All publications cited herein are incorporated by reference to disclose and describe the materials herein. Any use of the disclosures provided is for their disclosure prior to the filing date and any publication dates provided should be independently confirmed. The methods, compositions, and kits are provided as follows: Nothing herein should be construed as an admission that we do not have any right to antedate such publication.
[0013] As used in this specification and the appended claims, the singular forms "a," "an," and " and "the" are intended to include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. Accordingly, this statement should not be construed as limiting the scope of the claims. Serving as a literal justification for the use of any exclusive term or "negative" limitation It is intended to fulfill its share.
[0014] For clarity, the methods, compositions, and kits are described in the context of separate embodiments. It will be appreciated that certain features may also be provided in combination in a single embodiment. Conversely, methods, compositions, and techniques that are described in the context of a single embodiment, for the sake of brevity, may be The various features of the set may also be provided separately or in any suitable subcombination. All combinations of the embodiments are specifically embraced by this disclosure and are not to be construed as limiting the present invention. In the present invention, such combinations include operable processes and / or compositions. to the extent that each and every combination is individually and expressly disclosed. In addition, all of the embodiments described herein may be modified in any manner. Subcombinations of the above are also specifically encompassed by the methods, compositions, and kits, and are In the specification, each and every such subcombination is specifically referred to herein. and disclosed as if expressly disclosed.
[0015] As will be apparent to those of skill in the art upon reading this disclosure, each of the components described and illustrated herein may be Each of the embodiments may be combined with any of the other embodiments without departing from the scope or spirit of the method. Individual elements that can be easily separated or combined from any of the features of the embodiments. Any recited method may be executed in the order of events recited or in a logical order. The steps may be performed in any other order that is reasonably possible.
[0016] method As summarized above, the present disclosure provides a method for generating a nucleic acid library. contacting a single-stranded nucleic acid (ssNA) with a single-stranded nucleic acid binding protein (SSB); The method includes generating a bound ssNA. The method includes generating a bound ssNA with an SSB-bound ssNA and a first adaptor. The oligonucleotide and the SSB-binding ssNA hybridization region and the first amplicon A first splint oligonucleotide containing an adaptor oligonucleotide hybridization region. The combination further comprises combining the SSB-bound ss Hybridization to the terminal region of SSB-bound ssNA via the NA hybridization region a first splint oligonucleotide and a first adaptor oligonucleotide Hybridization region to the first adaptor oligonucleotide. resulting in the formation of a complex containing the first splint oligonucleotide induced by the As a result, the end of the first adaptor oligonucleotide is linked to the first end of the SSB-bound ssNA. In some embodiments, the combining is adjacent to the end of the SSB binding region. sNA, a second adaptor oligonucleotide, and an SSB-bound ssNA hybridization and a second adaptor oligonucleotide hybridization region. and a second splint oligonucleotide comprising the splint oligonucleotide, The resulting complex is a replica of the terminal region hybridized to the first splint oligonucleotide. The SSB-bound ssNA hybridization region is located at the terminal region of the opposite SSB-bound ssNA. A second splint oligonucleotide hybridized via the second adaptor region and A second adaptor oligonucleotide is attached via the adaptor oligonucleotide hybridization region. The second splint oligonucleotide hybridized to the nucleotide. This allows the end of the second adaptor oligonucleotide to be fused to the end of the first adaptor oligonucleotide. It is adjacent to the end of the SSB-bound ssNA opposite the end adjacent to the dinucleotide.
[0017] A second adaptor oligonucleotide and a second splint oligonucleotide are used. An exemplary embodiment in which ssNA is used is shown generally in FIG. It is produced from dsNA by denaturing A (e.g., produced from dsDNA). The top of Figure 1 shows dsNA 102. When 2 is denatured, the resulting ssNA is contacted with single-stranded nucleic acid binding protein (SSB). The SSB-linked ssNA is generated by the synthesis of dsNA 102. In this embodiment, the ssNA 104 is a first SSB-binding ssNA. The first adaptor oligonucleotide hybridized to the splint oligonucleotide 108 nucleotide 106, and hybridizes to a second splint oligonucleotide 112 The first splint is combined with a second adaptor oligonucleotide 110. Hybridization of oligonucleotide 108 to first adaptor oligonucleotide 106 The cleavage step cleaves the first adaptor oligonucleotide of the first splint oligonucleotide 108. The second splint oligonucleotide hybridization region 114. Hybridization of the nucleotide 112 to the second adaptor oligonucleotide 110 The second splint oligonucleotide 112 is fused to the second adaptor oligonucleotide. The first splint oligonucleotide is hybridized via the hybridization region 116. The SSB-binding NA 104 of the second splint oligonucleotide 112 and the second splint oligonucleotide 108 , hybridization with the first adaptor region 106, and the second adaptor region 110. The fusion forms a complex 122. Hybridization to the 5'-terminal region of SSB-bound ssNA 104 identifies the first splice. The first SSB-binding ssNA hybridization region of Lint oligonucleotide 108 The second splint oligonucleotide 112 has an SSB-binding ssNA Hybridization to the 3' end region of 104 is performed using a second splint oligonucleotide. via the second SSB-binding ssNA hybridization region 120 of the octide 112. The splint oligonucleotide is a ssNA oligonucleotide that is a ssNA oligonucleotide with an SSB bond. The hybridization regions hybridize to their corresponding terminal regions of the SSB-bound ssNA. When the adaptor oligonucleotide is resized, the end of the adaptor oligonucleotide becomes the end of the SSB-bound ssNA. The positions of the flanking ends are indicated by asterisks. The adjacent ends of the adaptor are covalently linked (e.g., by enzymatic ligation) to form an adaptor. By generating an adapter-attached ssNA (e.g., the adapter-attached ssNA 124 shown in FIG. 1), Then, the ssNA is subjected to one or more sequences in the adapter portion of the adapter-attached ssNA. The downstream application of interest (e.g., PCR amplification, next-generation sequencing, and and / or equivalents). As shown in FIG. Upon completion of the formation of the adapter-attached ssNA, perform any clean-up steps. One or more of the reagents or components of the complex, e.g., an enzyme used for covalent binding, a splitting agent, Such cleanup may be separated from the target oligonucleotide, SSB, and / or the like. Suitable approaches for the step-up include, but are not limited to, solid-phase These include reverse immobilization (SPRI - e.g., using magnetic beads) and nucleic acid column purification. In the example shown in FIG. 1, the blocking modification Blocking modifications are present at each end of the target oligonucleotide (black rectangles). The adapter oligonucleotide is further present at the end not adjacent to the SSB-bound ssNA. Blocking modifications are similar to those of oligonucleotides and ssNAs. This prevents ligation to these ends.
[0018] As summarized above, the nucleic acid sequence can be ligated to one or more adaptor sequences. The drawbacks associated with current methods for preparing determination libraries include the following: The method of the present disclosure includes the time and cost required for the preparation of the stencil. 017) Nucleic Acids Research 45(10):e79 Single-stranded libraries, such as the approach described in The method constitutes an improvement over the current state-of-the-art approach to the preparation of β-lactam α-lactams, and surprisingly, It has been found to be more efficient, require less time and reduce costs. Aspects of the disclosed methods will now be described in further detail.
[0019] The subject method comprises contacting a single-stranded nucleic acid (ssNA) with a single-stranded nucleic acid binding protein (SSB). "Single-stranded nucleic acid" or "ssNA" are single-stranded (i.e., intermolecular or molecular) over 70% or more of their length. In some embodiments, the term "polynucleotide sequence" refers to a set of polynucleotides that are not hybridized within a single molecule. In the form, the ssNA comprises 75% or more, 80% or more, 85% or more of the length of the polynucleotide. , 90% or more, 95% or more, or 99% or more single stranded. In this case, the ssNA is single stranded over the entire length of the polynucleotide.
[0020] ssNAs can be expressed in, but are not limited to, single cells, multiple cells (e.g., cultured cells), , including nucleic acid samples isolated from tissues, organs, or organisms (e.g., bacteria, yeast, etc.); It can be (or can be prepared from) any nucleic acid sample of interest. Exemplary Sample Types Examples include, but are not limited to, blood, serum, saliva, sputum, urine, feces, vomit, and mucus. , hair, nails (e.g., fingernails, toenails), swabs (e.g., buccal swabs, throat swabs, vaginal swabs), wabs), biopsy tissue (e.g. punch biopsy, fine needle biopsy, fine needle aspiration biopsy), cell cultures, environmental samples These include samples from samples (e.g., water, soil, air, surface, and touch DNA), and metagenomic samples. In certain embodiments, the nucleic acid sample is from a single cell, a collection of cells, a tissue, an organ, or the like of an animal. and / or the like. In some cases, the nucleic acid sample may be isolated from, but is not limited to, However, fetal cell-free nucleic acids (e.g., cell-free fetal DNA (cffDNA)) or circulating tumor Cell-free nucleic acids (e.g., cell-free DNA (ctDNA)) and other tumor nucleic acids (e.g., circulating tumor DNA (ctDNA)) In some embodiments, the animal is a mammal (e.g., a human). Mammals from the genus Musculus, rodents (e.g., mice or rats), dogs, cats, horses, cats, In other embodiments, the nucleic acid sample is from a bacterial, yeast, , insects (e.g., fruit flies), amphibians (e.g., frogs (e.g., African clawed frogs), mammalian, such as frogs, viruses, plants, or any other non-mammalian nucleic acid sample source; isolated / obtained from a source other than the subject.
[0021] In some embodiments, the ssNA is from a degraded nucleic acid sample. As used herein, a "degraded nucleic acid sample" refers to a sample that has been degraded by enzymatic, physical, chemical, or other processes. An example of a degraded nucleic acid sample is DNA recovered from bone residues. DNA fragments, hair, cell-free DNA from plasma, or environmental DNA recovered from soil or water In certain embodiments, when the ssNA is from a degraded nucleic acid sample, the ssNA is sNA is derived from ancient nucleic acid samples. "Ancient nucleic acid samples" are those derived from biological remains. Non-limiting examples of ancient nucleic acid samples of interest include those derived from extinct organisms or or an animal, e.g., an extinct mammal. In certain embodiments, the extinct mammal is from the genus Homo. In an embodiment, the ssNA is from a forensic nucleic acid sample. A "forensic nucleic acid sample" is a nucleic acid sample related to (e.g., obtained in the course of) a criminal investigation. It is a fee.
[0022] In certain embodiments, the ssNA is prepared from a tumor nucleic acid sample (i.e., nucleic acid isolated from a tumor). As used herein, a "tumor" refers to a tumor, whether malignant or benign. Regardless, the growth and proliferation of all neoplastic cells, and all precancerous and cancerous The terms "cancer" and "cancerous" refer to cells and tissues that are typically characterized by unregulated cell growth. Cancer refers to or describes a physiological condition in mammals that is characterized by rapid proliferation / growth. These include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More specific examples of such cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, and Lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, Ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer, colon cancer, colon cancer, endometrial cancer or uterine cancer , salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, various types of head and neck cancer Examples include cervical cancer.
[0023] In some embodiments, the ssNAs are prepared from a cell-free nucleic acid sample, e.g., cell-free DNA, cell-free In certain embodiments, the cell-free nucleic acid is from whole blood, cellular RNA, or both. , plasma, serum, amniotic fluid, saliva, urine, pleural fluid, bronchial lavage fluid, bronchial aspirate, breast milk, colostrum, tears The antibody is obtained from a body fluid sample selected from the group consisting of semen, peritoneal fluid, pleural fluid, and stool. In some embodiments, the cell-free nucleic acid is cell-free fetal DNA. The cell-free nucleic acid is circulating tumor DNA. In some embodiments, the cell-free nucleic acid is infectious In certain embodiments, the cell-free nucleic acid comprises DNA from the graft.
[0024] In certain embodiments, the ssNA is a single-stranded deoxyribonucleic acid (ssDNA). The target ssDNA includes ssDNA derived from double-stranded DNA (dsDNA), For example, ssDNA can be denatured (e.g., by heat treatment) to produce ssDNA. In some embodiments, the DNA may be derived from double-stranded DNA that has been denatured (and / or chemically denatured). The method comprises denaturing the dsDNA prior to contacting the ssDNA with SSB. The method includes generating ssDNA by
[0025] When the ssNA is ssDNA derived from a dsDNA sample, the method further comprises the steps of: , ssDNA (at this point one or more adapters (e.g., The sequence-determining adapter (including the dsDNA) is then rehybridized to generate dsDNA. If desired, the generated dsDNA can be sequenced. In an embodiment, rehybridization involves the formation of a dsDNA fragment similar to the original dsDNA from which the ssDNA was derived. The hybridization conditions are stringent enough to generate DNA. Sufficiently stringent hybridization conditions are those that are consistent with the selected hybridization sequences. The dsDNA was derived from the dsDNA synthesis process, the dsDNA synthesis temperature, the salt concentration selected, and / or the original dsDNA from which the ssDNA was derived. Any other convenient hybridization technique selected to generate dsDNA similar to NA. At least a subset of such generated dsDNA may include a dsDNA amplification parameter. One or both ends of the dsDNA fragment are analogous to the ends of the original dsDNA (e.g., overhangs). Using the methods of the present disclosure (e.g., by sequencing), Determining the overhang content can provide valuable insight into various properties of the nucleic acid sample from which the ssDNA was derived. For example, knowing the overhang content can provide useful information for, e.g., plasma or other It is worthwhile to analyze cell-free DNA (cfDNA) from a suitable source. A is a type of cell that can be detected in blood cells, fetal cells from pregnant women, tumor cells from individuals with cancer, and cells from organ transplant recipients. It has been shown that the cells can be derived from a variety of sources, including transplant organ tissue. The overhang content provided by the embodiments may vary depending on the source, e.g., for diagnostic purposes. It can be used to classify sequencing reads.
[0026] In addition, end / overhang content is a valuable tool for analyzing mixed DNA from forensic samples. For example, DNA from semen, blood, or another source of interest may be used. The DNA sequence may have terminal features that are diagnostic for the gene, and the DNA sequence may be divided based on this information. do.
[0027] In addition, in ancient DNA samples (e.g., samples from extinct organisms, plants, or animals), Determining the overhang content can be used to identify such samples and the organisms from which they are derived. Provides useful information for characterizing plants, animals, etc. For example, ancient DNA samples (e.g. For example, DNA samples from extinct mammals often contain contaminating DNA (e.g., contaminating bacterial In such cases, such types of overhangs may be used to identify specific DNA. When associated with the A source, the DNA sequence of interest is identified based on the type of overhang detected. can be separated from contaminating DNA sequences.
[0028] In certain embodiments, the methods of the present disclosure include a function of the length and type of overhang. To determine the rate and location of base damage in DNA extracts (e.g., ancient DNA extracts), Find uses for it when determining
[0029] Thus, in some embodiments, ssDNA derived from SSB-bound dsDNA is In combination with the adapter and splint oligonucleotides described herein, SSB-bound dsDNA hybridized to the primer and splint oligonucleotides The formation of a complex containing A-derived ssDNA and the re-assembly of the ssDNA after the complex formation Hybridize to produce dsDNA that is similar to the original dsDNA from which the ssDNA was derived (i.e. and containing one or more adaptors (e.g., sequencing adaptors) at one or both ends. and generating "adapted" dsDNA containing the nucleotide sequence of the present invention. The method may further comprise sequencing the adapted dsDNA. Sequencing determines the end / overhang content of the dsDNA from which the ssDNA was derived. In any embodiment of the disclosed method involving sequencing, the method comprises: Subsample ssNA with adapters to reduce complexity during determination The method may include sequencing the
[0030] In some embodiments, the ssNA is a single-stranded ribonucleic acid (ssRNA). RNA includes, but is not limited to, messenger RNA (mRNA), miRNA, small interfering RNA (siRNA), transacting small molecule Small interfering RNA (ta-siRNA), naturally occurring small interfering RNA (nat-siRNA), Bosomal RNA (rRNA), transfer RNA (tRNA), small nucleolar RNA (s noRNA), small nuclear RNA (snRNA), long non-coding RNA (lncRNA) ), non-coding RNA (ncRNA), transfer messenger RNA (t mRNA), precursor messenger RNA (pre-mRNA), small Cajal body-specific R NA (scaRNA), piwi-interacting RNA (piRNA), endoribonucleic acid RNA-edited siRNA (esiRNA), small temporal RNA (stRNA), signal recognition RNA, telomeric RNA, ribozyme, or any such RNA type or subunit In some embodiments, the ssNA is ssR If the ssRNA is NA, the ssRNA is mRNA.
[0031] Applications for isolating, purifying, and / or concentrating DNA and RNA from a source of interest Approaches, reagents, and kits are known in the art and commercially available. For example, kits for isolating DNA from a source of interest include those available from Qiagen, Inc. DNeasy®, RNeasy® by Eppendorf, Inc. (Germantown, Md.) trademark), QIAamp®, QIAprep®, and QIAqui ck® Nucleic Acid Isolation / Purification Kit; Life Technologies, Inc. (Carlsbad, CA) ch (registered trademark), Purelink (registered trademark), GeneCatcher (registered trademark) ) Nucleic acid isolation / purification kit; Clontech Laboratories, Inc. (M NucleoMag®, Nucleo oSpin® and NucleoBond® Nucleic Acid Isolation / Purification Kits In certain embodiments, nucleic acids are obtained from fixed biological samples, e.g., formalin. Isolated from phosphorus-fixed paraffin-embedded (FFPE) tissue. Genomic DNA from FFPE tissue NA was obtained from AllPrep by Qiagen, Inc. (Germantown, Md). (Registered Trademark) DNA / RNA FFPE Kit, Life Technologies, RecoverAll (registered trademark) for FFPE by Inc. (Carlsbad, CA) (Trademark) Total Nucleic Acid Isolation Kit, and Clontech Laboratories, Inc. NucleoSpin® FFP by NucleoSpin, Inc. (Mountain View, CA) It can be isolated using commercially available kits such as the E kit.
[0032] The organism, plant, animal, etc. from which the nucleic acid sample was obtained (e.g., isolated) is extinct Suitable strategies for recovering such nucleic acids are known, for example, Green et al. al. (2010) Science 328(5979):710-722, Poina r et al. (2006) Science 311(5759):392-394, Stiller et al.(2006)Proc.Natl.Acad.Sci.1 03(37):13578-13584, Miller et al. (2008)Na ture 456(7220):387-90, Rasmussen et al.(2 010) Nature 463(7282):757-762, and elsewhere. This includes those that are currently being investigated.
[0033] As summarized above, the subject method comprises binding ssNA to single-stranded nucleic acid binding proteins (SSBs). ) to generate SSB-bound ssNA. SSB binds to ssNA cooperatively. It binds in a ssDNA manner and does not bind well to double-stranded nucleic acid (dsNA). SSBs that can be used in carrying out the subject methods include Examples of SSBs include prokaryotic SSBs (e.g., bacterial or archaeal SSBs) and eukaryotic SSBs. Non-limiting examples of SSB that can be used in practicing the subject methods include E. coli. i SSB, E. coli RecA, extremely thermostable single-stranded DNA binding protein (ET SSB), Thermus thermophilus (Tth) RecA, T4 gene ET protein 32, and replication protein A (RPA - eukaryotic SSB). SSB, Tth RecA, E. coli RecA, T4 gene 32 protein, NAR The buffer and detailed process for preparing SSB-bound ssNA using the SSB are also described. The protocol is, for example, that described in detail in the literature by New England Biolabs, Inc. (Ipswich, NY, USA). ch, MA). We hypothesize that, assuming equimolar inputs, For ssNAs with larger average fragment lengths, a larger input of SSB is beneficial. In order to generate SSB-bound ssNA, ssNA is contacted with SSB. Detailed guidance on example approaches for this purpose is provided in the Experimental Section below. can be.
[0034] As summarized above, the subject method comprises the steps of: (a) synthesizing a ssNA bound to an SSB and an adaptor oligonucleotide; The oligonucleotide and the SSB-bound ssNA hybridization region and the adapter oligonucleotide A splint oligonucleotide containing a nucleotide hybridization region is combined with the splint oligonucleotide. As used herein, "oligonucleotide" refers to a compound that is formed by combining the oligonucleotide with a nucleic acid. " is a single-stranded multimer of 5 to 500 nucleotides, e.g., 5 to 100 nucleotides. Oligonucleotides may be synthetic or enzymatically produced. In some embodiments, the oligonucleotide is 5 to 50 nucleotides in length. Nucleotide monomers (i.e., oligoribonucleotides or "RNA oligonucleotides") deoxyribonucleotide monomers (i.e., oligodeoxyribonucleotides, which may be a polynucleotide or a "DNA oligonucleotide"), or a combination thereof. The oligonucleotide may include, for example, 10 to 20, 20 to 30, 30 to 4 0, 40~50, 50~60, 60~70, 70~80, 80~100, 100~150 , or 150-200, or up to 500 nucleotides in length.
[0035] An "adapter oligonucleotide" of the present disclosure is an oligonucleotide that includes an adapter or a portion thereof. An "adapter" is a polynucleotide that is a conjugate of an nucleotide sequence that is used for one or more downstream applications (e.g., PCR amplification of ssNA or its derivatives, ssNA or its derivatives with adapter "A nucleotide sequence useful for the determination of the sequence of a particular In embodiments, the adapter or a portion thereof present in the adapter oligonucleotide is "Sequencing adapter" refers to an Illumina® Sequencing platforms provided by q™ and / or Genome Analyzer™ sequencing systems ), Oxford Nanopore™ Technologies (e.g., IonION™ Sequencing System), Ion Torrent™ (e.g., Ion n PGM™ and / or Ion Proton™ sequencing systems); Pacific Biosciences (e.g., Sequel or PacBio RS II Sequencing System), Life Technologies™ (e.g. , SOLiD™ Sequencing System), Roche (e.g., 454 GS FLX + and / or GS Junior sequencing system), or any other sequence of interest. The nucleic acid sequence utilized by the sequencing platform of interest, such as a sequencing platform. The present invention relates to one or more nucleic acid domains that contain at least a portion of a nucleic acid sequence (or its complement). Taste.
[0036] In certain embodiments, the sequencing adaptors are surface-bound sequencing platform oligomers. A oligonucleotide (e.g., a flow cytometer in an Illumina® sequencing system) A domain that specifically binds to the P5 or P7 oligonucleotide bound to the surface of a cell. a "capture site" or "capture sequence"); a sequencing primer binding domain (e.g., For example, the read 1 or read 2 primers of the Illumina® platform a domain to which a target polypeptide can bind; a unique identifier (e.g., an oligonucleotide probe, a uniquely identifies the 3' region of the probe, complementary strand oligonucleotide, or both; and and / or to map all molecules from a given sample using a specific barcode or “tag.” The sample source of sequenced rRNA was optimized to allow for sample multiplexing by matching the uniquely identifying the target gene, a barcode or other domain, barcode sequencing primer binding Binding domains (domains to which primers used for sequencing barcodes bind), e.g. For example, a sequence of interest can be used to determine expression levels based on the number of events in which a unique tag is sequenced. A molecular identification domain (e.g., 4, 6, or other number of nucleotides) to uniquely mark the molecule. a molecular index tag, such as a randomized tag for a nucleic acid fragment, or any combination thereof. In certain embodiments, the barcode domain (e.g., sample index tag) and molecular identification domains (e.g., molecular index tags) may be contained in the same nucleic acid. good.
[0037] When the adapter oligonucleotide comprises one or a portion of a sequencing adapter, one or more further sequencing adaptors and / or remaining portions of the sequencing adaptors can be added using a variety of approaches. For example, additional portions of the sequencing adaptor and / or the remaining part is subjected to ligation, reverse transcription, PCR amplification, and / or In the case of PCR, a 3' hybridization region (e.g. , for hybridizing to the adapter region of the adapter oligonucleotide), and a 5' region containing a further portion and / or a remainder of the sequencing adaptor. The first amplification primer and the 3' hybridization region (e.g., the 3' hybridization region of the ssNA molecule) The second adaptor oligonucleotide is added to the opposite end of the hybridization site. for re-mapping), and optionally further parts of the sequencing adapter and / or a second amplification primer comprising the 5' region containing the remaining portion, and It can be used.
[0038] The "splint oligonucleotides" of the present disclosure are SSB-binding ssNA hybridizers. The oligonucleotide hybridization region includes an adaptor oligonucleotide hybridization region. The SSB-binding ssNA hybridization region is a SSB-binding A region (nucleotide sequence) that hybridizes to the terminal region of ssNA. Adapter The oligonucleotide hybridization region is the site of all of the adapter oligonucleotides. A splint oligo is a region (nucleotide sequence) that hybridizes to all or part of a Upon complex formation, the end of the adaptor oligonucleotide is bound to the SSB bond. The SSB-bound ssNA and the adaptor oligonucleotide are attached adjacent to the end of the terminal region of the ssNA. The nucleic acid is designed for simultaneous hybridization to two oligonucleotides.
[0039] The SSB-binding ssNA hybridization region of the splint oligonucleotide is It may have any suitable length and sequence. In some embodiments, the SSB-binding ssNA The length of the hybridization region is 10 nucleotides or less. The SSB-binding ssNA hybridization region is 4 to 20 nucleotides in length, e.g. For example, 5–15, 5–10, 5–9, 5–8, or 5–7 (e.g., 6 or 7) nuclei. In some embodiments, SSB-bound ssNA hybridization A region may comprise (e.g., consist of) a random nucleotide sequence and thus may have a variety of random Multiple heterogeneous splints with dam SSB-binding ssNA hybridization regions When oligonucleotides are used, the assembly is the sequence of the terminal region of the SSB-binding ssNA. Sprint oligonucleotide synthesis for heterogeneous populations of SSB-bound ssNA regardless of column It can function as a
[0040] Thus, in certain embodiments, the method comprises the steps of: Due to the non-uniform population of SSB-bound ssNAs with nucleotides and terminal regions of undetermined sequence Various random SSB binding sites that can serve as splint oligonucleotides Multiple non-uniform splint oligonucleotides with ssNA hybridization regions The present invention includes forming a complex by combining with an
[0041] In some embodiments, the SSB-binding ssNA hybridization region is a known A known sequence was designed to hybridize to the SSB-binding ssNA terminal region of the sequence. In certain embodiments, the known sequences are each hybridized to the SSB-binding ssNA terminal region. SSB-binding ssNA hybridases with different known sequences were designed to hybridize with each other. Two or more heterogeneous splint oligonucleotides having a splint region are used. An embodiment in which the SB-binding ssNA hybridization region has a known sequence is, for example, A nucleic acid library is created from only a subset of SSB-bound ssNAs with terminal regions of known sequences. The method finds use where it is desirable to generate a cyclic nucleotide sequence. The method comprises combining an SSB-linked ssNA with an adaptor oligonucleotide and one or more of a known sequence. A splint oligonucleotide for one or more SSB-binding ssNAs having a terminal region of One or more distinct SSB-binding ssNA hybrids of known sequence that can act as a and one or more heterogeneous splint oligonucleotides having a ligation region. The term includes combining to form a complex.
[0042] In certain embodiments, the SSB-binding ssNA hybridization region comprises one or more As used herein, a "universal base" includes any of the four Can base pair indiscriminately with each of the standard nucleotide bases: A, C, G, and T A universal base that can be incorporated into the SSB-bound ssNA hybridization region. Salicylic bases include, but are not limited to, 2'-deoxyinosine (dI, dIn osine and 5-nitroindole.
[0043] SSB-bound ssNA, adapter oligonucleotides, and splint oligonucleotides The method of combining the oxidases can vary. In some embodiments, the combination The adapter oligonucleotide hybridization region is used to bind the adapter oligonucleotide. a complex comprising a splint oligonucleotide hybridized to the nucleotide; In another embodiment, the combining step comprises combining with an SSB-bound ssNA. Hybridization to SSB-bound ssNA via the SSB-bound ssNA hybridization region A complex containing a fused splint oligonucleotide and an adaptor oligonucleotide. In yet another embodiment, the combining includes combining an SSB bond with a tide. The ssNA, adapter oligonucleotide, and splint oligonucleotide were combined. Any of the three components may be premixed with another component prior to combination. Therefore, they are not complexed (i.e., hybridized).
[0044] The combination allows the complex to bind to the SSB-binding ssNA hybridization domain. The splint oligonucleotide hybridized to the terminal region of the SSB-bound ssNA was The adapter oligonucleotide hybridization region is connected to the adapter oligonucleotide. and a splint oligonucleotide hybridized to the oligonucleotide. The hybridization is carried out under hybridization conditions. Whether or not the splint oligonucleotide is present is determined by the associated (i.e., hybridization) activity of the splint oligonucleotide. a region that binds to the SSB-binding ssNA, a terminal region of the SSB-binding ssNA, and an adaptor oligonucleotide. The degree of complementarity between the The temperature at which the melting occurs (the melting temperature of the relevant region (T M ) may be informed by The melting temperature is determined by the temperature at which half of the relevant region remains hybridized and It refers to the temperature at which half of the relevant region dissociates into single strands. The Tm of a double strand is calculated according to the following formula: Tm=8 1.5+16.6(log10[Na + ]) + 0.41 (G + C ratio) - (60 / N) can be experimentally determined or predicted using the formula: + ]teeth Less than 1M. Sambrook and Russell (2001; lar Cloning:A Laboratory Manual,3rd ed., Cold Spring Harbor Press,Cold Spring Har See Bor NY, Ch.10. Other methods that depend on various parameters Advanced models also allow the Tm of relevant regions to be determined under various hybridization conditions. It can be used to predict specific nucleic acid hybridization. Approaches to this are, for example, Tijssen, Laboratory Techniqu es in Biochemistry and Molecular Biology -Hybridization with Nucleic Acid Probes, part I,chapter 2,“Overview of principles of hybridization and the strategy of nu cleic acid probe assays,” in Elsevier (1993). It can be found.
[0045] As used herein, the term "complementary" or "complementarity" refers to a region of a target nucleic acid. Non-covalently base-paired nucleotide sequences, e.g., the termini of SSB-bound ssNA Nucleotide sequence of the SSB-bound ssNA hybridization region that hybridizes to the region and an adaptor oligonucleotide that hybridizes to the probe complementary oligonucleotide. Canonical Watson- refers to the nucleotide sequence of the oligonucleotide hybridization region. In Crick base pairing, guanine (G) forms a base pair with cytosine (C) in DNA. Adenine (A) base pairs with thymine (T) so that in RNA, thymine is a reverse transcriptase. A is replaced by U. Thus, A is complementary to T and G is complementary to C. In RNA, A is complementary to U and vice versa. Typically, "Complementary" or "complementarity" refers to at least partially complementary nucleotide sequences. These terms also refer to the fact that every nucleotide in one strand is identical to every nucleotide in the other strand at the corresponding position. It also includes a completely complementary duplex, where every nucleotide is complementary. In other words, the nucleotide sequence may be partially complementary to the target, in which case all corresponding At each position, all nucleotides are complementary to all nucleotides in the target nucleic acid. For example, the SSB-binding ssNA hybridization region may be SS It may be completely (i.e., 100%) complementary to the terminal region of the B-linked ssNA, or The SSB-bound ssNA hybridization region may be partially (e.g., Two nucleotides may share complementarity (70%, 75%, 85%, 90%, 95%, 99%). The percent identity of the polypeptide sequences is best determined by aligning the sequences for comparison purposes. For example, gaps may be inserted in the sequence of the first sequence for optimal alignment. The nucleotides at the corresponding positions are then compared to determine the sequence identity between the two sequences. The percent identity is a function of the number of identical positions shared by the sequences (i.e., (i.e., % identity = number of identical positions / total number of positions × 100). When the corresponding positions in the A non-limiting example of such a mathematical algorithm is Karlin e t al.,Proc.Natl.Acad.Sci.USA 90:5873-587 7 (1993). Such an algorithm is described in Altschul et al. al., Nucleic Acids Res.25:389-3402(1997) The NBLAST and XBLAST programs (version 2. 0) using the BLAST and Gapped BLAST programs. When using the program, the default parameters of each program (e.g., NBLAST) should be used. In one aspect, parameters for sequence comparison can be used: score=100, The word length can be set to 12 or can be changed (e.g., word length = 5 or word length=20).
[0046] The complex is formed by integrating the end of the adaptor oligonucleotide with the end of the terminal region of the SSB-bound ssNA. "Adjacent to" refers to the adaptor oligonucleotide that is formed adjacent to the end of the adaptor oligonucleotide. the terminal nucleotide at the terminus and the terminal nucleotide end of the terminal region of the SSB-bound ssNA are sufficiently close to each other that their terminal nucleotides can be easily linked by, for example, chemical ligation. This means that the molecule can be covalently linked by polymerization, enzymatic ligation, etc. In this form, their ends are terminated with terminal nucleotides at the ends of adapter oligonucleotides. The splint oligonucleotide is connected to the terminal nucleotide end of the terminal region of the SSB-bound ssNA. They are adjacent to each other by hybridizing to adjacent nucleotides of the nucleotide sequence. The print oligonucleotide is a ssSb-linked adaptor oligonucleotide. Such a spring may be designed to ensure that it is adjacent to the end of the terminal region of the NA. Non-limiting examples of oligonucleotides are provided in the experimental section herein.
[0047] Any of the methods described herein may comprise the step of: The covalent linkage may further comprise covalently linking the adjacent ends to the B-linked ssNA. Ligation of adjacent ends may include ligating adjacent ends. Ligation of adjacent ends may include Any suitable approach may be used. In certain embodiments, ligation In another embodiment, the ligation is by enzymatic ligation. Suitable reagents for carrying out enzymatic ligation reactions (e.g. For example, ligases and corresponding buffers and kits are known and are available from, for example, Ne Inst available from England Biolabs (Ipswich, MA). ant Sticky-end Ligase Master Mix is available Ligases that can be used include, for example, T4 DNA ligase (e.g., low concentration or (high concentration), T4 DNA ligase, T7 DNA ligase, E. coli DNA ligase Ligase, ElectroLigase (registered trademark), etc. Suitable conditions for carrying out the reaction will vary depending on the type of ligase used. Information regarding the conditions for which this can be done is readily available. The adapter oligonucleotide is cleaved using a suitable kinase, such as protease kinase (PNK). A phosphate group can be added to the 5' end of the ssNA bound to SSB. Guidance for using such kinases to phosphorylate the 5' end can be found in, for example, Ne Available from England BioLabs, Inc. (Ipswich, MA). It is.
[0048] In some embodiments, the splint oligonucleotide, the adaptor oligonucleotide The splint oligonucleotide, the nucleotide sequence, or both contain blocking modifications. One or both ends of the peptide may contain a blocking modification and / or may be SSB-binding The end of the adaptor oligonucleotide not adjacent to the sNA contains a blocking modification. "Blocking modification" refers to the modification of the adapter oligonucleotide and the SSB-binding ss Using the approach used to covalently link adjacent ends of NA, This means that the oligonucleotide moiety is incapable of being ligated to the terminus of another oligonucleotide moiety. In this embodiment, the blocking modification is a modification that blocks ligation. One or both ends of the primer oligonucleotide and / or the adapter oligonucleotide Blocking modifications that may be included at the end of the nucleotide that is not adjacent to the SSB-bound ssNA An example of the modification is the adapter oligonucleotide on the side not adjacent to the SSB-bound ssNA. Absence of 3'OH at the terminus and adapter oligo on the side not adjacent to SSB-bound ssNA The terminus of a nucleotide is an inaccessible 3'OH. Non-limiting examples of blocking modifications having a 3'OH include amino modifiers, spacers, -, dideoxy base, inverted dideoxy base, 3' phosphate, etc.
[0049] In certain embodiments, the splint oligonucleotide, the adaptor oligonucleotide , or both, may contain one or more non-natural nucleotides (also called nucleotide analogs). A splint oligonucleotide, an adaptor oligonucleotide, or Non-limiting examples of non-natural nucleotides that can be included in both are LNA (locked nucleic acid), PNA (peptide nucleic acid), FANA (2'-deoxy-2'-fluoroarabinonucleoside) tide), GNA (glycol nucleic acid), TNA (threose nucleic acid), 2'-O-Me RN A, 2'-fluoro RNA, morpholino nucleotides, and any combination thereof It is.
[0050] The adjacent ends of the adaptor oligonucleotide and the SSB-bound ssNA are covalently linked. By this, an adapted ssNA is generated, where "adapted" means means that the ssNA comprises one or more adapter sequences or subregions thereof. The ssNA with adapter is used as input in the intended downstream application. For example, the complex may be purified by ligating the adaptor-tagged ssNA to a splint oligonucleotide. The nucleotides may be denatured (e.g., heat denatured) to separate them from the adaptor-attached ss NAs can be purified by SSB and / or other methods (e.g., solid-phase reversible immobilization (SPRI), column purification, and / or equivalent) during the contacting and / or combining steps. or combinations thereof.
[0051] In some embodiments, the one or more adapter sequences or subregions thereof include one or more or a subregion thereof, and the method comprises the steps of: Its derivatives (e.g., ssNA with adaptor) can be used as templates for PCR amplification. and sequencing at least a portion of the amplified products produced thereby. is a high-throughput sequencing (HTS) (or "next-generation sequencing (NGS)") platform. The method may be performed on any suitable sequencing platform, including any suitable platform such as the genomic sequencing platform. HTS / NGS sequencing platforms include, but are not limited to, Ill Sequencing platforms provided by umina (e.g., HiS eq™, MiSeq™, and / or Genome Analyzer( (trademark) sequencing system), Oxford Nanopore (trademark) Technology gies (e.g., MinION (trademark), GridIONx5 (trademark), Promet hION™, or SmidgION™ nanopore-based sequencing system ), Ion Torrent™ (e.g., Ion PGM™ and / or Ion Proton™ Sequencing System, Pacific Biosciences ces (e.g., Sequel or PacBio RS II sequencing systems), L ife Technologies™ (e.g., the SOLiD Sequencing System); Roche (e.g., 454 GS FLX+ and / or GS Junior sequencing) Direct sequencing ( For example, by nanopore-based sequencing) or sequencing on a specific platform 2. preparing a nucleic acid molecule suitable for isolating a nucleic acid fragment (e.g., by amplification, e.g., solid phase amplification) of sequencing the matched molecules and analyzing the sequencing data. Detailed protocols for sequencing are available from the manufacturer of the desired sequencing platform. be.
[0052] As summarized above, the methods of the present disclosure are based on the methodology described by Gansauge et al. ) Described by Nucleic Acids Research 45(10):e79 For single-stranded library preparation, such as the approach being proposed (referred to as "ssDNA2.0"), This method constitutes an improvement over the current state-of-the-art approaches to It has been found that the process is more efficient, requires less time, and reduces costs. In an embodiment, the method comprises the steps of: If the procedure involves covalently linking the ends of the fusion protein to each other, the total time for the combining and covalent linking steps is is 4 hours or less, 3 hours or less, 2 hours or less, or 1 hour or less. The method further comprises: forming an adapter oligonucleotide and an SSB-linked ssNA fragment adjacent to each other at the same end; When covalent bonding is included, the total time for the contacting, combining, and covalent bonding steps is , 4 hours or less, 3 hours or less, 2 hours or less, or 1 hour or less. In this case, the efficiency of the method is such that 70% or more of the ssNA contacted with the SSB during the contacting step is 75% or more. % or more, 80% or more, 85% or more, 90% or more, 95% or more, or 99% or more It is what allows the body to be formed.
[0053] composition As summarized above, the present disclosure also provides compositions. The compositions may, for example, comprise any of the compositions described herein. Performing any one or more of the steps described above in the method part of The present invention can be used in a variety of applications, including performing any of the methods of the present disclosure, including Thus, the composition may comprise an oligonucleotide as described above in the method section of the present disclosure. Nucleotides (including multiples / assemblies of non-uniform oligonucleotides), ssNA, SSB, etc. The reagents may include any of the reagents listed above, in any combination.
[0054] In certain embodiments, a SSB-linked ssNA and a first adaptor oligonucleotide , SSB-bound ssNA hybridization region and the first adaptor oligonucleotide and a first splint oligonucleotide comprising an octide hybridization region. A composition is provided, the composition comprising a second adaptor oligonucleotide and an SSB Combined ssNA hybridization region and second adaptor oligonucleotide and a second splint oligonucleotide comprising a hybridization region. do.
[0055] In certain embodiments, the hybridized complex exists (e.g., SSB complex). In the absence of synthetic ssNA, the adapter oligonucleotide hybridization region A splint oligonucleotide hybridized to an adapter oligonucleotide via In another aspect, a composition is provided that comprises a complex containing the tide. SSB-binding ssNA hybridization domains exist as a single unit. Compositions Comprising Complexes Comprising Splint Oligonucleotides Hybridized to ssNAs Things are provided.
[0056] The ssNA may be ssDNA. When the ssNA is ssDNA, the ssDNA is It may be derived from dsDNA. In some embodiments, the ssNA is ssRNA. In some embodiments, the ssNA is from a degraded nucleic acid sample. In embodiments, when the ssNA is from a degraded nucleic acid sample, the ssNA is from an extinct organism. A nucleic acid sample obtained (e.g., isolated) from an object or animal, e.g., an extinct mammal. In certain embodiments, the extinct mammal is a human. In some embodiments, the ssNA is from a forensic nucleic acid sample. That is why.
[0057] The disclosed compositions attach the adaptor oligonucleotide end to the end of the SSB-linked ssNA. The reagent may further comprise a reagent for covalent attachment. In some embodiments, the reagent is a chemical An igation reagent or an enzymatic ligation reagent, for example a ligase.
[0058] The compositions of the present disclosure may include one or more components that are present in a container. Suitable containers include Examples of suitable materials include, but are not limited to, tubes, vials, and plates (e.g., 96-well plates). well plate or other well plate).
[0059] In certain embodiments, the composition comprises one or more components in a liquid medium. The liquid medium may be an aqueous liquid medium such as water, a buffer solution, etc. One or more additives, e.g., salts (e.g. For example, NaCl, MgCl2, KCl, MgSO4), buffers (Tris buffer, N-(2 -hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2 -(N-morpholino)ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid Morpholinoic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS ), N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS ), solubilizing agents, detergents (e.g., non-ionic detergents such as Tween-20), nucleic acids, etc. Lyase inhibitors, glycerol, chelating agents, and the like may be present in such compositions.
[0060] kit As summarized above, the present disclosure provides kits. The kits may include, for example, carrying out any one or more of the steps set forth above in the section of the Act. The present invention can be used in a variety of applications, including performing any of the methods of the present disclosure. Thus, the kit includes the oligonucleotides described above in the method section of this disclosure. oligonucleotides (including multiple / assembly of non-uniform oligonucleotides), ssNA, SSB, other reagents The compositions may include any of the following drugs, in any combination:
[0061] In some embodiments, the kits of the present disclosure include a single-stranded nucleic acid binding protein (SSB, e.g. For example, single-stranded DNA-binding proteins, single-stranded RNA-binding proteins, or both) and 1. Hybridization of the first adaptor oligonucleotide and the SSB-bound ssNA a first adaptor oligonucleotide hybridization region and a first adaptor oligonucleotide hybridization region; a splint oligonucleotide, an SSB, a first adaptor oligonucleotide, and and instructions for generating a nucleic acid library using a first splint oligonucleotide. In certain embodiments, such a kit includes a second adaptor oligonucleotide. The hybridization region of the SSB-bound ssNA and the second adaptor oligonucleotide are and a second splint oligonucleotide comprising the nucleotide, SSB, the first adaptor oligonucleotide, the first splint oligonucleotide a second adaptor oligonucleotide, and a second splint oligonucleotide. to generate a nucleic acid library using
[0062] The kit of the present disclosure is a method for attaching an adaptor oligonucleotide end to an end of an SSB-linked ssNA. The reagent may further comprise a reagent for covalent attachment. In some embodiments, the reagent is a chemical An igation reagent or an enzymatic ligation reagent, for example a ligase.
[0063] In some embodiments, the splint oligonucleotide, the adaptor oligonucleotide The splint oligonucleotide, the nucleotide sequence, or both contain blocking modifications. One or both ends of the peptide may contain a blocking modification and / or may be SSB-binding The end of the adaptor oligonucleotide not adjacent to the sNA contains a blocking modification. In certain aspects, the blocking modification is a modification that blocks ligation. One or both ends of the splint oligonucleotide and / or the SSB A block that may be included at the end of the adaptor oligonucleotide that is not adjacent to the bound ssNA An example of a modification is the addition of an adaptor oligonucleotide to the non-adjacent side of the SSB-bound ssNA. Absence of 3'OH at the end of the oxidase and the adapter on the side not adjacent to the SSB-bound ssNA - An inaccessible 3'OH at the end of an oligonucleotide. Non-limiting examples of blocking modifications that result in an inaccessible 3'OH include amino Modifiers, spacers, dideoxy bases, inverted dideoxy bases, 3' phosphates, etc. Some examples include:
[0064] In some embodiments, one or more of the splints provided in the kits of the present disclosure. The oligonucleotide is an SSB that comprises (e.g., consists of) a random nucleotide sequence. The kit contains a combination of ssNA hybridization regions, allowing the kit to detect a variety of random SSBs. Multiple heterogeneous splint oligonucleotides with linked ssNA hybridization regions In the case where the set includes a nucleic acid sequence similar to that of the terminal region of the SSB-binding ssNA of interest, Regardless of splint oligonucleotides for heterogeneous populations of SSB-binding ssNA It can function as:
[0065] In certain aspects, the splint oligonucleotide provided in the kit of the present disclosure comprises: Contains an SSB-binding ssNA hybridization region that contains one or more universal bases. Universal salts that can be incorporated into the ssNA hybridization region of SSB binding Groups include, but are not limited to, 2'-deoxyinosine (dI, dInosin e) and 5-nitroindole.
[0066] In some embodiments, the splint oligonucleotides provided in the kits of the present disclosure The length of the SSB-binding ssNA hybridization region of the oxidase is 10 nucleotides or less. In certain embodiments, the SSB-binding ssNA hybridization region is 4 ~20 nucleotides in length, e.g., 5-15, 5-10, 5-9, 5-8, or 5-7 ( For example, 6 or 7) nucleotides in length.
[0067] The components of the subject kits may be present in separate containers, or multiple components may be present in a single Suitable containers include a single tube (e.g., a vial), Plates with more than 100 wells (e.g., 96-well plates, 384-well plates, etc.) etc. are included.
[0068] SSB, one or more adaptor oligonucleotides, and one or more splint oligonucleotides Instructions for generating a nucleic acid library using the oligonucleotides can be stored on a suitable recording medium. For example, the instructions can be printed on a substrate such as paper or plastic. As such, the instructions may be provided in the kit as a package insert, on the kit container or in any of its components. It may be present on an ingredient label, etc. (i.e., associated with the packaging or subpackaging). In this state, the instructions are stored on a portable flash drive, DVD, CD-ROM, or diskette. As an electronic storage data file residing on a suitable computer-readable storage medium, such as In yet other embodiments, the actual instructions are not present in the kit, but are, e.g., Means are provided for obtaining instructions from a remote source via the Internet. An example embodiment is a website where the instructions can be viewed and / or the instructions can be downloaded. The kit includes a block address. The instructions, as well as the means for obtaining the instructions, are provided on a suitable substrate. will be recorded.
[0069] The following examples are offered by way of illustration and not by way of limitation. EXAMPLES
[0070] experiment Example 1 Rapid, efficient and targeted adapter ligation to single-stranded DNA in one reaction Disclosed herein is an approach for the application of Illumina A sequencing adaptor oligonucleotide containing a P7 or P5 adaptor sequence is A series of 3 Prime N for sprints and a series of 5 Prime N for P5 sprints The splint is hybridized to a splint oligonucleotide containing the immunogen N. The adapter is targeted to a single stranded ligase that can perform single strand ligation with high efficiency. Creates an opportunity for DNA ligation. All oligonucleotide DNA ends that are not required are ligated to the oligonucleotide ends, which prevents ligation. The oligonucleotide is blocked by a modification (eg, an amino modification).
[0071] The addition of single-stranded binding protein (SSB) to the assay increases the efficiency of the reaction. Use the appropriate DNA concentration and length to achieve optimal ligation efficiency. Calculate the amount of SSB that is sufficient for the reannealing of single-stranded DNA while preventing secondary structures. Rings can be prevented.
[0072] This method, known as SS2.0, was developed by Gansauge et al. 17) Nucleic Acids Research 45(10):e79 Compared to previously described single-stranded library preparations, SS2.0 This method requires significantly less time and produces suitable adaptor ligated fragments that can be sequenced. This approach exhibits a significantly increased efficiency of DNA conversion into clonal DNA molecules. , reducing reagent costs compared to SS2.0.
[0073] Adapter and splint oligonucleotides are prepared using appropriate adapter ligation All ends that should not participate in the synthesis carry modifications that block ligation. This involves the 5 prime end of the P5 adaptor, the 3 prime end of the P7 adaptor, This includes blocking the lyme end and all ends of the splint. Ligation blocking modifications include amino modifiers, carbon spacers, and dideoxy bases. , or a 3-prime hydroxyl group at the 3-prime end or a 5-prime hydroxyl group at the 5-prime end It may be any other suitable modification that prevents access of the ligase to the immunophosphate. The oligonucleotides can be prepared, for example, by using the method described in Integrated DNA Technology. es (IDT). Exemplary oligonucleotides are shown in Table 1 below. [Table 1]
[0074] In the protocol used in this example, template DNA is combined with SSB, Heat denaturation. After denaturation, reactions were placed on ice or on a PCR cooler at 4°C. Cooling Afterwards, adapters were added to each reaction. Then reaction master mix was added, followed by mixing. Ligation begins immediately upon incubation at 37°C and can be continued for up to 45 minutes. Most ligations occur in 10 min. The reaction is cleaned up using established methods. and downstream applications such as amplification and sequencing remain unchanged.
[0075] To prepare the adapters, use P5 adapter at a final concentration of 10uM and 2 0 µM P5 splint oligonucleotide with 1x final concentration of T4 RNA ligase Combined with buffer (Cat. No. B0216L). P7 adapter and P7 split A similar separate mixture was prepared using the control oligonucleotide. 95°C for 10 sec. Heat the adapter by then ramping down to 10 °C at a rate of 0.1 °C / sec. The hybridization was performed using the same method as described above.
[0076] An example protocol is provided below. 1. Sample input (36uL) a. Shear DNA and ET SSB (Cat. No. M2401S) in a volume of 36 uL Combined with i.1uL of ET SSB was found to be inhibitory for most sample types tested. Promotes ligation without ii. Buffer EBT (10 mM Tris-HCl, pH 8.0, and 0.05% Fill the remaining volume with Tween 20 2. Sample Denaturation a. Incubate samples for 3 min in a thermocycler with the lid preheated to 95 °C do b. Immediately place the denatured samples on ice or a PCR cooler for 30 seconds. 3.2 uL of pooled adapter mix (equal volumes of P5 and P7 adapters ) is added a. Adaptor input depends on the molar concentration of the input. A low ratio of adapter to template is preferred. 4. Add reaction master mix and mix thoroughly by pipetting a. 8uL of T4 DNA Ligase Buffer (Cat. No. M0202M) b. 32uL of 50% PEG 8000 (Cat. No. B0216L) c. 1 uL of T4 Polynucleotide Kinase-10,000 U / mL (Cat. No. M0201L) d. 1 uL of T4 DNA Ligase - 2,000,000 U / mL (Cat. No. M 0202M) 5. Incubate at 37°C for up to 60 minutes. a. Most ligation occurs in the first 15 minutes, but plateaus by about 45 minutes. Not achieved. 6. Clean up the reaction a. Column cleanup (e.g., for degraded DNA) or SPRI (e.g., for modern for samples).
[0077] Comparison and optimization assays After cleanup, qPCR was performed on dilutions of the pre-amplified libraries and ligated The conversion efficiency was determined. A lower CT value was obtained by comparing the conversion efficiency with another sample of the same experiment that had a higher CT value. This shows a higher ligation efficiency compared to the original sample. A difference of 1 represents a 2-fold increase in library efficiency. An aliquot of the pre-amplified library was also used in the index PCR reaction. After indexing, the libraries were cleaned with SPRI and amplified using the Agilent Visibility on the TapeStation 2200 system to identify adapters in each library The proportion of tumor artifacts was estimated.
[0078] Single-stranded binding protein Single-stranded binding proteins (SSsB proteins) such as the ET SSB protein supplied by the NEB B) was observed to improve the ligation efficiency of single-stranded ligation. Given equal molar concentrations of input, samples with higher average fragment lengths have higher peak lengths. A larger input of SSB was required to achieve gating. The molar concentration of NA also influences the amount of SSB required. ET SSB is in huge excess. If so, it has the potential to inhibit ligation.
[0079] Protocol Comparison The efficiency of this protocol was evaluated using the NEB Ultra 2 kit (dsDNA), SS2.0 ( Gansauge et al. (2017) Nucleic Acids Resea rch 45(10):e79), and Caroe et al. (2017)Me thods in Ecology and Evolution 9(2):410- 419 and Mak et al. (2017) GigaScience 6:1-13 The results were compared with the blunt-ended single-tube (BEST) method described in Modern human DNA has an average fragment length of 0 bp, whereas ancient bison DNA has an average fragment length of about 35-40 bp and is highly degraded. Comparative results were obtained using samples and
[0080] The NEB Ultra 2 kit provides a highly efficient library preparation method for modern samples. While SS2.0 is a highly efficient method for degraded samples, The BEST protocol is recognized as a reliable library preparation method for T4 DNA polymerase. DNA was blunt-ended (without tails) and 5'-ends were created using 5'-dimerase and T4 PNK. Next, T4 DNA ligase is used to repair the blunt ends. A blunt-ended dsDNA adapter was ligated to the blunt end of the primer, followed by Bst 2.0 Warmstart polymerase was used to fill in the reaction, and SPRI beads or Use a column for cleanup.
[0081] The comparative results are presented in Figure 2. From left to right in the top panel, the methods described in this example From left to right in the bottom panel, The method described in the Examples (asterisk), NEB Ultra 2 kit, ss 2.0, and BEST. The method described in this example is For the modern samples, this results in a much higher ligation efficiency. The method described in the Examples of the present invention uses 0.3-0.5 qPC from the NEB Ultra 2 kit. R cycle delayed.
[0082] Example 2 - Hair DNA DNA was collected from hair using standard proteinase K treatment at high temperature. Six nanograms of DNA was used as a template to generate the libraries described above. The protocol was followed to generate two sequencing labels from the adapter ligation products. Two libraries were generated: one using 1 μL of the total ligation product of 50 μL; The other used 2.5 μL of this product (SRL4). The library was sequenced on an Illumina MiSeq sequencing platform. The characteristics and complexity (number of unique library molecules) of the libraries were assessed.
[0083] After paired-end sequencing of 2 × 75 fragments, the overlapping fragments were analyzed using the SeqPrep program. The forward and reverse read pairs that overlap the original DNA were combined. The template is short enough that the forward and reverse reads have some similarity. This occurs when the reads cover a sequence (herein referred to as "merged reads"). After sequencing, the merged and unmerged reads were matched to the reference human genome sequence. Figure 3 shows the results for both the SRL3 and SRL4 libraries. , merged and mapped, merged but not mapped, and The distribution of observed original template lengths for reads that were sequenced but not mapped. In the case of non-merged and non-mapped sequences, the length of the template DNA is estimated. It is not possible to do so.
[0084] The Preseq software program was used to identify unique sequences in both libraries. The program estimates the number of library molecules observed, as generated here. To model the complexity of a nucleic acid library from a large sample of reads, we The program counts the number of duplicate molecules that are detected at various depths of library sequencing. Figure 4 shows estimates for the fraction of observed reads predicted to be unique. As shown in Figure 1, both libraries have a complexity of over 250,000,000 unique molecules. The DNA fragment was generated from 2.5 μL of the adaptor-ligated template. The isolated SRL4 has more unique molecules than SRL3.
[0085] Example 3 – Ancient DNA from bison bones Using DNA extracted from ancient bison bones, a sequencer was created from a template DNA molecule. The efficiency of conversion to the library was compared using four different protocols, including the protocol described above. Libraries were generated from the same amounts of DNA from the same extracts using col.
[0086] Two approaches were used: qPCR and direct sequencing of adapter ligation products. Library complexity was measured using a qPCR assay. qPCR estimates were performed in triplicate. Figure 5 Both approaches shown in are useful in converting DNA into a sequencing library. The approach described here proves to be more efficient.
[0087] Thus, the foregoing merely illustrates the principles of the present disclosure. Although not explicitly described or illustrated herein, any embodiment embodying the principles of the present invention may be used. It will be understood that various arrangements can be devised which fall within the spirit and scope of the present invention. All examples and conditional phrases described in the specification are based on the principles of the present invention and the inventors' ideas. The primary intent is to aid the reader in understanding concepts that contribute to the advancement of the art. The present invention is not intended to be a limitation on the specific examples and conditions described herein. The principles, aspects, and embodiments of the present invention, as well as specific examples thereof, are described below. All statements herein encompass both structural and functional equivalents thereof. Additionally, such equivalents include both currently known equivalents and future equivalents. Both the equivalents developed in the future, i.e. any development that performs the same function regardless of structure, Accordingly, the scope of the present invention is limited to the extent that it is applicable to any of the embodiments shown and described herein. It is not intended to be limited to the exemplary embodiments depicted.
Claims
1. 1. A method for generating a nucleic acid library, comprising: Contacting a single-stranded nucleic acid (ssNA) with a single-stranded nucleic acid binding protein (SSB) generating a conjugated ssNA; The SSB-bound ssNA, a first adaptor oligonucleotide, and SSB-bound ssNA hybridization region and first adaptor oligonucleotide A first splint oligonucleotide comprising a nucleotide hybridization region. Combining Including, The SSB-bound ssNA hybridization region is connected to the SSB-bound ssNA hybridization region. the first splint oligonucleotide hybridized to the terminal region of A; The first adaptor is connected to the first adaptor via a first adaptor oligonucleotide hybridization region. The first splint oligonucleotide hybridized to the adapter oligonucleotide. forming a complex containing the nucleotide of the first adaptor oligonucleotide, The method, wherein the terminus is adjacent to the terminus of the terminal region of the SSB-binding ssNA.
2. The first adaptor oligonucleotide and the adjacent ends of the SSB-bound ssNA The method of claim 1 further comprising covalently linking the ends.
3. The total duration of the contacting, combining, and covalent bonding steps is 3 hours or more. The method of claim 2, wherein
4. The complex is formed from 80% or more of the ssNA contacted with the SSB. The method according to any one of claims 1 to 3.
5. 5. Any one of claims 1 to 4, wherein the ssNA is from a degraded nucleic acid sample. The method described above.
6. The method of claim 5, wherein the ssNA is from an ancient nucleic acid sample.
7. The method according to any one of claims 1 to 6, wherein the ssNA is from a forensic nucleic acid sample. Method of posting.
8. The method according to any one of claims 1 to 7, wherein the ssNA is single-stranded DNA (ssDNA). The method described.
9. The method of claim 8, wherein the ssDNA is derived from double-stranded DNA (dsDNA). How to.
10. By denaturing the dsDNA prior to contacting the ssDNA with SSB.
10. The method of claim 9, further comprising generating the ssDNA.
11. After the complex is formed, the ssDNA is rehybridized to produce dsDNA. The method of claim 9 or claim 10, further comprising:
12. 12. The method of claim 11, further comprising sequencing the generated dsDNA. 。
13. The method of claim 12, wherein a subsample of the generated dsDNA is sequenced. 。
14. The ssNA is a single-stranded RNA (ssRNA), The method described.
15. The combining, via the first adaptor oligonucleotide hybridization region The first splint oligonucleotide hybridized to the first adaptor oligonucleotide. a complex comprising a dinucleotide; The SSB-bound ssNA The method of any one of claims 1 to 14, comprising combining
16. The combining, The SSB-bound ssNA hybridization region is connected to the SSB-bound ssNA hybridization region. A complex comprising the first splint oligonucleotide hybridized to A; the first adaptor oligonucleotide; The method of any one of claims 1 to 14, comprising combining
17. The combining, The SSB-bound ssNA; a second adaptor oligonucleotide; and SSB-bound ssNA hybridization region and second adaptor oligonucleotide a second splint oligonucleotide comprising a nucleotide hybridization region; and further comprising combining The formed complex is a complex comprising the first splint oligomer of the SSB-bound ssNA. The SS is provided in a terminal region opposite to the terminal region hybridized to the nucleotide sequence of The second sequence hybridized via the B-linked ssNA hybridization region The print oligonucleotide and the second adaptor oligonucleotide hybridize. The second adaptor oligonucleotide is hybridized to the second adaptor oligonucleotide via a The second splint oligonucleotide is further comprised in said second splint oligonucleotide, thereby The end of the adapter oligonucleotide is the first adapter of the SSB-binding ssNA. - adjacent to the end opposite to the end adjacent to the oligonucleotide, claims 1 to 16 2. The method according to claim 1 .
18. The second adaptor oligonucleotide and the adjacent ends of the SSB-bound ssNA. The method of claim 17, further comprising covalently linking the ends.
19. said covalently linking comprises ligating said adjacent ends. Item 19. The method according to any one of items 1 to 18.
20. The method of claim 19, wherein the ligation is performed by enzymatic ligation. Law.
21. The end of the adaptor oligonucleotide that is not adjacent to the SSB-bound ssNA is 21. The method according to any one of claims 1 to 20, comprising a blocking modification.
22. 22. The method of claim 21, wherein the blocking modification is a modification that blocks ligation. Method of posting.
23. The blocking modification is a SSB binding site of the adaptor oligonucleotide. The absence of a 3'OH at the end not adjacent to the sNA and the Inaccessibility at the end of the nucleotide that is not adjacent to the SSB-bound ssNA 23. The method of claim 21 or 22, wherein the 3'OH is selected from the group consisting of:
24. The blocking modification is a modification of the SSB binding site of the adaptor oligonucleotide. an inaccessible 3'OH at the end not adjacent to the sNA; The modifications include amino modifiers, spacers, dideoxy bases, inverted dideoxy bases, and 24. The method of claim 23, wherein the 3' phosphate is selected from the group consisting of:
25. The SSB-binding ssNA hybridization region comprises a random sequence.
25. The method of any one of 1 to 24.
26. The SSB-binding ssNA hybridization region comprises a universal base. The method according to any one of claims 1 to 25.
27. The length of the SSB-binding ssNA hybridization region is 10 nucleotides or less. The method according to any one of claims 1 to 26, wherein
28. The adapter oligonucleotide is an adapter for PCR amplification or its complement. The method of any one of claims 1 to 27, comprising administering to said subject a therapeutically effective amount of
29. The adaptor oligonucleotide may be a partial or complete sequencing adaptor or The method of any one of claims 1 to 28, wherein:
30. Further comprising sequencing at least a portion of the ssNA or a derivative thereof.
30. The method according to any one of claims 1 to 29.
31. A single-stranded nucleic acid bound to a single-stranded nucleic acid binding protein (SSB-bound ssNA); a first adaptor oligonucleotide; SSB-bound ssNA hybridization region and first adaptor oligonucleotide a first splint oligonucleotide comprising an octide hybridization region; A composition comprising:
32. a second adaptor oligonucleotide; and SSB-bound ssNA hybridization region and second adaptor oligonucleotide a second splint oligonucleotide comprising an octide hybridization region; 32. The composition of claim 31 further comprising:
33. 32. The method of claim 31, wherein the ssNA is from a degraded nucleic acid sample. The composition described in
34. The composition of claim 33, wherein the ssNA is from an ancient nucleic acid sample.
35. 34. Any one of claims 31 to 33, wherein the ssNA is from a forensic nucleic acid sample. The composition described in
36. Any one of claims 31 to 35, wherein the ssNA is single-stranded DNA (ssDNA). The composition according to item 3.
37. 37. The method of claim 36, wherein the ssDNA is derived from double-stranded DNA (dsDNA). The composition described above.
38. Any one of claims 31 to 35, wherein the ssNA is single-stranded RNA (ssRNA). The composition according to item 3.
39. The adaptor oligonucleotide end is covalently attached to the end of the SSB-bound ssNA. The composition of any one of claims 31 to 38, further comprising a reagent for:
40. 40. The composition of claim 39, wherein the reagent is a ligase.
41. Single-stranded nucleic acid binding protein (SSB); a first adaptor oligonucleotide; SSB-bound ssNA hybridization region and first adaptor oligonucleotide a first splint oligonucleotide comprising an octide hybridization region; The SSB, the first adaptor oligonucleotide, and the first splint oligonucleotide Instructions for generating a nucleic acid library using the nucleotides. Including the kit.
42. a second adaptor oligonucleotide; and SSB-bound ssNA hybridization region and second adaptor oligonucleotide a second splint oligonucleotide comprising an octide hybridization region; Further comprising: The instructions include a sequence for determining whether the SSB, a first adaptor oligonucleotide, a first splint oligonucleotide, a second adaptor oligonucleotide, and a second splint oligonucleotide.
42. The method of claim 41, wherein the oligonucleotide is used to generate a nucleic acid library. Kit included.
43. The method according to claim 41 or 42, wherein the SSB is a single-stranded DNA binding protein. Net.
44. The method according to claim 41 or 42, wherein the SSB is a single-stranded RNA binding protein. Net.
45. The end of the adaptor oligonucleotide is attached to a single-stranded nucleic acid binding protein. 41 to 4, further comprising a reagent for linking to the end of the nucleic acid (SSB-linked ssNA).
5. The kit according to any one of claims 4 to 4.
46. 46. The kit of claim 45, wherein the reagent is a ligase.
47. 47. The adaptor oligonucleotide of claim 41, wherein the end of the adaptor oligonucleotide comprises a blocking modification. The kit according to any one of claims 1 to 5.
48. 48. The method of claim 47, wherein the blocking modification is a modification that blocks ligation. Kit included.
49. The blocking modification is a modification of the SSB binding site of the adaptor oligonucleotide. The absence of a 3'OH at the end not adjacent to the sNA and the Inaccessibility at the end of the nucleotide that is not adjacent to the SSB-bound ssNA 49. The kit of claim 47 or claim 48, wherein the 3'OH is selected from the group consisting of:
50. The blocking modification is a modification of the SSB binding site of the adaptor oligonucleotide. an inaccessible 3'OH at the end not adjacent to the sNA; The modifications include amino modifiers, spacers, dideoxy bases, inverted dideoxy bases, and 3' phosphates. to.
51. The SSB-binding ssNA hybridization region comprises a random sequence.
41. The kit according to claim 41 to 50.
52. The SSB-binding ssNA hybridization region comprises a universal base. The kit according to claims 41 to 51.
53. The length of the SSB-binding ssNA hybridization region is 10 nucleotides or less. The kit according to claims 41 to 52,
Citation Information
Patent Citations
Mate pair library construction
WO2016058517A1
Efficiency improving ligation methods
WO2016156529A1
